Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study)
Por:
Redondo A, Girones R, Ruiz N, Iglesias M, Mendiola C, Santaballa A, Manzano A, Rubio M, Mallol P, Tornamira M, Jimenez M, Gonzalez-Martin A
Publicada:
15 dic 2021
Resumen:
Objective: To assess epidemiological, pathological and clinical characteristics, therapeutic management patterns and outcomes in the management of advanced ovarian cancer (AOC) in clinical practice. Methods: Multicenter, retrospective, epidemiological, observational real-world study reviewing clinical records from 277 patients diagnosed with AOC between January 2008 and December 2010 who were treated and followed in 31 Spanish hospitals belonging to the Spanish Ovarian Cancer Research Group (GEICO). Survival curves were estimated by Kaplan-Meier and differences analyzed by the log-rank test. Results: Median age at diagnosis was 62 years (range 26-96), 62% of patients had a high-grade serous carcinoma, and 64% and 21% of patients had stage IIIC and stage IV disease, respectively. Overall, 46% of patients underwent primary debulking surgery (PDS), with complete cytoreduction in 63% of procedures, and 34% underwent interval debulking surgery, with complete cytoreduction in 71% of them. Overall, 96% of patients received at least one cycle of front-line chemotherapy. Recurrence occurred in 77% of patients, and 90% of them (69% of total) received a second line chemotherapy. Median progression-free survival (PFS) was 14 months (95% CI: 13-17) and median overall survival (OS) was 41 months (95% CI: 34-49). PDS and complete cytoreduction had a statistically significant correlation with PFS and OS. Conclusions: This retrospective study provides real-world data of clinical characteristics, therapeutic management, and outcomes in Spanish AOC patients. Primary debulking surgery and complete cytoreduction were favorable prognostic factors in this series.
Filiaciones:
Redondo A:
Univ Autonoma Madrid UAM, Hosp Univ La Paz, IdiPAZ, Serv Oncol Med, Madrid 28049, Spain
Girones R:
Hosp Univ & Politecn La Fe, Serv Oncol Med, Valencia 46026, Spain
Ruiz N:
Consorcio Hosp Prov Castellon, Serv Oncol Med, Castellon de La Plana 12006, Spain
Iglesias M:
Hosp Univ Son Llatzer, Serv Oncol Med, Palma De Mallorca 07198, Spain
Mendiola C:
Hosp Univ 12 Octubre, Serv Oncol Med, Madrid 28041, Spain
Santaballa A:
Hosp Univ & Politecn La Fe, Serv Oncol Med, Valencia 46026, Spain
Manzano A:
Hosp Univ Clin San Carlos, Serv Oncol Med, Madrid 28040, Spain
Rubio M:
Univ Cordoba UCO, Hosp Univ Reina Sofia, Serv Oncol Med, Cordoba 14014, Spain
Mallol P:
Fdn Invest Clin IVO FINCIVO, Unidad Ensayos Clin, Valencia 46009, Spain
Tornamira M:
MSD Spain, Calle Josefa Valcarcel 38, Madrid 20027, Spain
Jimenez M:
MSD Spain, Calle Josefa Valcarcel 38, Madrid 20027, Spain
Gonzalez-Martin A:
Clin Univ Navarra, Dept Oncol, Madrid 28027, Spain
gold
|